here's a fact:
when this company was operating, their gross revenues never exceeded 5% of their FORECAST gross revenues. That's right, the CEO missed his guidance by 95% every time he gave guidance.
Here's another: this company defaulted on EVERY loan they took out after MacLellan became CEO.
Here's another: they haven't filed a financial report since 4th Qtr 2011.
Here's another: after MacLellan took over and Jade mutinied and the only income was from onko-sure, the highest annual gross revenue total was $314,000 (in 2011). Operating expenses were $10 million that year (not counting the debt). That is the best the company ever did from an operations standpoint: gross revenues about 10% of operating costs.
Another fact: If you add the other expenses, this company lost about $85 million per year the last two years it operated (2010 and 2011).
Anyone clamoring for some kind of resurrection of this company and/or DR-70 has to answer one important question: WHY? Biotech is all about profits and making money. A developmental biotech can burn cash like that because there is a CHANCE it will be profitable some day, but when it gets FDA clearance for its flagship product (as AMDL did in 2006), the CEO has to meet his guidance, or the company dies. This company is proof that a biotech cvan't just get FDA clearance -- it has to SELL something; and patents are worthless if the device is not profitable.
